UNSPSC 51313413: Pheniramine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 134FM9ZZ6M, chemically known as 3-phenyl-3-(2-pyridyl)-n,n-dimethylpropylanine but generally known as pheniramine, which bears US NIH Compound Identifier 4761. European Medicines Agency schedules Pheniramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09768MIG.

UNSPSC 51313413 Pheniramine, a Commodity code, nominally covers a single antihistamine agent, but recent state and local procurement activity under this code shows little direct solicitation for pheniramine itself. Instead, the opportunities tagged to this code involve broader pharmaceutical procurement — naloxone and drug deactivation systems for public health use, direct-to-manufacturer pharmacy benefit initiatives, and multi-source generic pharmaceuticals and OTC products for government health systems. The actual buying pattern reflects state health departments, county health agencies, and cooperative purchasing alliances acquiring pharmaceutical products and related services to support community health, emergency response, and institutional pharmacy operations, rather than pheniramine specifically. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon state and local facilities).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) soliciting vendor capabilities for a direct-to-manufacturer pharmacy prescription program; and the Minnesota Department of Administration's MMCAP S1070000015802 (posted January 20, 2026, response deadline March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local government facilities. The code shows modest recent activity dominated by cooperative purchasing and state-level procurement mechanisms rather than fragmented solicitations, with emphasis on compliance with cGMP, DSCSA, and FDA requirements, and pricing competitiveness as a primary evaluation factor.